Richard Brudnick
Richard Brudnick's purchase track record
Richard Brudnick has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2025 | PRME | $24K | +175.7% | +202.1% | +11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Transaction History
| SRRK | ▲ Buy | Grant | 6,839 | $0 | 6/4/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 4,675 | $139K | 5/29/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,400 | $42K | 5/29/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 7,632 | $0 | 5/22/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 20,000 | $24K | 5/20/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| VNRX | ▲ Buy | Grant | 5,625 | $0 | 1/12/2023 | View on chart |
| VNRX | ▲ Buy | Grant | 2,625 | $0 | 10/13/2022 | View on chart |
| VNRX | ▲ Buy | Grant | 3,046 | $0 | 6/23/2022 | View on chart |
| VNRX | ▲ Buy | Grant | 1,640 | $0 | 4/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.